SOST and osteoporosis: Romosozumab is a monoclonal antibody that binds and inhibits sclerostin.10 It exerts a dual effect on bone by increasing bone formation and decreasing bone resorption.10 The Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) study compared the effect of romosozumab versus placebo on the cumulative incidences of new VFxs at 12 and 24 months in postmenopausal women with osteoporosis.